Oramed Pharmaceuticals

Oramed Pharmaceuticals EBITDA per Employee

The EBITDA per Employee of Oramed Pharmaceuticals (ORMP) as of Nov 7, 2026 is -1.26 M USD. In the previous year, EBITDA per Employee was -1.07 M USD — a change of 18.05% (lower).

EBITDA per Employee

-1.26 MUSD

YoY

18.05%

Last updated:

EBITDA per Employee of Oramed Pharmaceuticals is 2025 -1.26 M USD. EBITDA per Employee of Oramed Pharmaceuticals was 2024 -1.07 M USD. It decreases by 18.05% lower compared to the previous year.

The Oramed Pharmaceuticals EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-1.13 M USD
Jan 1, 2019
-1.22 M USD
Jan 1, 2020
-979,750.00 USD
Jan 1, 2021
-2.02 M USD
Jan 1, 2022
-3.38 M USD
Jan 1, 2023
-1.31 M USD
Jan 1, 2024
-1.07 M USD
Jan 1, 2025
-1.26 M USD
The Oramed Pharmaceuticals EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.26 MUSD+18.05%
-1.07 MUSD-18.95%
-1.31 MUSD-61.16%
-3.38 MUSD+67.73%
-2.02 MUSD+105.88%
-979,750.00USD-19.64%
-1.22 MUSD+8.16%
-1.13 MUSD+25.59%
-897,583.33USD+7.60%
-834,166.67USD+35.58%
-615,250.00USD+25.01%
-492,166.67USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oramed Pharmaceuticals Stock analysis

What does Oramed Pharmaceuticals do? Oramed Pharmaceuticals Inc is an innovative biotech company headquartered in Jerusalem, Israel. The company was founded in 2006 by Nadav Kidron and specializes in the development of oral forms of protein-based therapeutics. The idea behind Oramed Pharmaceuticals was to revolutionize the way proteins are administered. Typically, protein-based drugs like insulin need to be administered in injectable form, which can be unpleasant and painful for many patients. Oramed Pharmaceuticals set out to find a solution to this problem. The company has developed a technology called ORMD-0801, which allows for the oral administration of insulin. The active ingredient is protected by a special capsule that monitors the pH level in the stomach. Once the capsule reaches the small intestine, the active ingredient is released and can be absorbed by the body. Oramed Pharmaceuticals aims to improve the treatment of diabetes. With the oral form of insulin, patients can take their medication much easier and more conveniently. This can help improve treatment and increase patients' quality of life. In addition to the development of ORMD-0801, Oramed Pharmaceuticals is also working on developing oral forms of other protein-based therapeutics. The company has filed a variety of patents for technologies and therapies and actively collaborates with other companies and research institutions. Oramed Pharmaceuticals has two main divisions: the development department and the commercialization department. The development department is responsible for the research and development of new therapies, while the commercialization department is responsible for sales and marketing of the products. Oramed Pharmaceuticals' business model is focused on developing innovative therapies and bringing them to market. The company works closely with other companies and research institutions to advance the development of new therapies. Oramed Pharmaceuticals is currently working on several projects to develop additional orally administered protein-based therapeutics. In addition to insulin, the company is also working on proteins that can be used in the treatment of other diseases such as osteoporosis and Parkinson's. The products of Oramed Pharmaceuticals are of great importance to both patients and the medical community. The oral forms of protein-based therapeutics can help make the treatment of diabetes and other diseases much easier and more convenient. This can help increase patient satisfaction and improve compliance. In recent years, Oramed Pharmaceuticals has received several awards and accolades for its innovative products. The company continues to work on developing new therapies and changing the way medication is administered. Oramed Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oramed Pharmaceuticals stock

EBITDA per Employee of Oramed Pharmaceuticals is -1.26 M USD in 2025.

EBITDA per Employee of Oramed Pharmaceuticals changed from -1.07 M USD to -1.26 M USD, representing a 18.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Oramed Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Oramed Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Oramed Pharmaceuticals

All Key Metrics — Oramed Pharmaceuticals